PDCD1 and non-small cell lung carcinoma: B. breve was found to be significantly higher in patients who had a better PFS than those who did not, among a cohort of Chinese NSCLC patients treated with anti-PD-1, suggesting its presence as a potential indicative biomarker for better prognosis [73].